Canada markets closed
  • S&P/TSX

    +101.62 (+0.48%)
  • S&P 500

    +33.17 (+0.74%)
  • DOW

    +198.70 (+0.56%)

    +0.0005 (+0.06%)

    -0.31 (-0.37%)

    +2,233.81 (+2.91%)
  • CMC Crypto 200

    +17.48 (+1.19%)

    +2.40 (+0.14%)
  • RUSSELL 2000

    +8.07 (+0.36%)
  • 10-Yr Bond

    +0.0510 (+3.22%)
  • NASDAQ futures

    -20.75 (-0.13%)

    -0.61 (-3.74%)
  • FTSE

    +13.70 (+0.19%)
  • NIKKEI 225

    +194.25 (+0.66%)

    -0.0001 (-0.01%)

Benign Prostatic Hyperplasia Pipeline Landscape Report 2021: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type -

·4 min read

DUBLIN, September 28, 2021--(BUSINESS WIRE)--The "Benign Prostatic Hyperplasia - Pipeline Insight, 2021" clinical trials has been added to's offering.

This Benign Prostatic Hyperplasia - Pipeline Insight, 2021 provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Benign Prostatic Hyperplasia pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Benign Prostatic Hyperplasia R&D. The therapies under development are focused on novel approaches to treat/improve Benign Prostatic Hyperplasia.

Benign Prostatic Hyperplasia Emerging Drugs Chapters

This segment of the Benign Prostatic Hyperplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Benign Prostatic Hyperplasia Emerging Drugs

Fexapotide: Nymox Pharmaceutical

Fexapotide (NX-1207) is a pro-apoptotic injectable protein and is in development for the treatment of benign prostatic hyperplasia. In May 2021, Nymox Pharmaceutical announced that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before September 15, 2021.

AIV007: AiViva BioPharma

AIV007 is a novel formulation using company's JEL Technology designed for prolonged drug release. AIV007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis, and it also modulates TGF?1 mRNA expression and TGF-1 levels to prevent and inhibit cell proliferation. AIV007 is currently in clinical studies for neovascular macular degeneration (nAMD) treatment and in preclinical studies for benign prostatic hyperplasia (BPH), and certain solid tumors.

Major Players in Benign Prostatic Hyperplasia

There are approx. 12+ key companies which are developing the therapies for Benign Prostatic Hyperplasia. The companies which have their Benign Prostatic Hyperplasia drug candidates in the most advanced stage, i.e. Preregistration include, Nymox Pharmaceutical.


This report covers around 12+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Benign Prostatic Hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Benign Prostatic Hyperplasia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Benign Prostatic Hyperplasia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Benign Prostatic Hyperplasia drugs.

Benign Prostatic Hyperplasia Report Insights

  • Benign Prostatic Hyperplasia Pipeline Analysis

  • Therapeutic Assessment

  • Unmet Needs

  • Impact of Drugs

Benign Prostatic Hyperplasia Report Assessment

  • Pipeline Product Profiles

  • Therapeutic Assessment

  • Pipeline Assessment

  • Inactive drugs assessment

  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Benign Prostatic Hyperplasia drugs?

  • How many Benign Prostatic Hyperplasia drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Benign Prostatic Hyperplasia?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Benign Prostatic Hyperplasia therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Benign Prostatic Hyperplasia and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Nymox Pharmaceutical

  • ASKA Pharmaceutical

  • Otsuka Pharmaceutical

  • Aiviva BioPharma

  • Veru Helathcare

  • Boryung Pharmaceutical

  • KAEL-GemVax

  • Dong-A ST/Mezzion

Key Products

  • Fexapotide

  • AKP009

  • Tolvaptan

  • AIV007

  • Tamsulosin delayed-release

  • BR9006

  • Tertomotide

  • Udenafil

For more information about this clinical trials report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting